Wedbush raised the firm’s price target on Solid Biosciences (SLDB) to $17 from $14 and keeps an Outperform rating on the shares. The firm is increasing its SGT-003 revenue estimates and assumes launch in FY28. Should an accelerated pathway emerge, Wedbush sees upside to the high-$20s. Solid remains a top pick for longer-term investors, says Wedbush.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences: INSPIRE DUCHENNE Data and FDA Pathway Support Overweight/Buy Rating on SGT-003 Gene Therapy Upside
- Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data
- Solid Biosciences: Strengthened Dystrophin Data and Emerging Cardiac Benefits Support Buy Rating on SGT-003
- Solid Biosciences trading resumes
- Solid Biosciences says interim results reinforce confidence in SGT-003 potential